Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRECONY therapeutic equivalence study of CHF5993 propellant formulations in mild to moderate asthma
PACTR202605842542989Phase 2Recruiting
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium and beclomethasone dipropionate in asthma (3 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Change from baseline in FEV1 AUC0-4h on Day 1 and Pre-dose FEV1 on Day 28. Started Mar 2026; status: recruiting.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrroniumbeclomethasone dipropionate
03
Conditions
asthma
Beyond the preview
Go deeper on PACTR202605842542989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202605842542989.